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Background aims. Reactivation of cytomegalovirus (CMV) after hematopoietic stem cell transplantation remains a major
cause of morbidity despite improved antiviral drug therapies. Selective restoration of CMV immunity by adoptive transfer of
CMV-speciﬁc T cells is the only alternative approach that has been shown to be effective and non-toxic. We describe the
results of clinical-scale isolations of CMV-speciﬁc donor lymphocytes with the use of a major histocompatibility (MHC) class
I peptide streptamer-based isolation method that yields minimally manipulated cytotoxic T cells of high purity. Methods.
Enrichment of CMV-speciﬁc cytotoxic T lymphocytes (CTLs) was performed by labeling 1  1010 leukocytes from a non-
mobilized mononuclear cell (MNC) apheresis with MHC class I streptamers and magnetic beads. Thereafter, positively
labeled CMV-speciﬁc CTLs were isolated through the use of CliniMACS (magnetic-activated cell sorting), and MHC
streptamers were released through the use of d-biotin. The purity of enriched CMV-speciﬁc CTLs was determined on the
basis of MHC streptamer staining and ﬂuorescence-activated cell sorting. Results. A total of 22 processes were performed
with the use of ﬁve different MHC class I streptamers. The median frequency of CMV-speciﬁc CTLs in the starting
apheresis product was 0.41% among CD3þ T cells. The isolation process yielded a total of 7.77  106 CMV-speciﬁc CTLs,
with a median purity of 90.2%. Selection reagents were effectively removed from the ﬁnal cell product; the CMV-speciﬁc
CTLs displayed excellent viability and cytotoxicity and were stable for at least 72 h at 4C after MNC collection. Conclusions.
Clinical-scale isolation of “minimally manipulated” CMV-speciﬁc donor CTLs through the use of MHC class I streptamers
is feasible and yields functional CTLs at clinically relevant dosages.
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Figure 1. Schematic view of the reversible MHC streptamer
technology. MHC class I peptide streptamer complexes are soluble
complexes of four synthetic Strep-tag labeled b2-microglobulin/
MHC class I monomers loaded with an antigenic peptide. By use
of multimerization with StrepTactin, an exponential increase in
avidity is created to generate stable binding of MHC streptamers
to its cognate TCRs (1). Labeling of StrepTactin, which functions
as “backbone” for the streptamer complex, with ﬂuorochromes or
magnetic microparticles allows speciﬁc visualization and/or
enrichment of antigen-speciﬁc CTLs in combination with FACS
or MACS. The multimeric peptide MHC class I streptamers can
easily be disassembled by the addition of d-biotin because the af-
ﬁnity of d-biotin to the Strep-tag binding sites signiﬁcantly exceeds
the afﬁnity of Strep-tag to StrepTactin (2). Because of their low
afﬁnity, peptide-MHC class I monomers dissociate from their
cognate TCR spontaneously within seconds, leaving “untouched”
T cells (3).
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drugs diminishes the risk of early-onset CMV disease
after chemotherapy and hematopoietic stem cell
transplantation (HSCT) but is frequently associated
with substantial organ toxicity, for example, nephro-
toxicity, the development of late-onset CMV disease
(4e8), impaired immune reconstitution leading to
fungal infections and bacterial sepsis (2,9) and, as a
result of viral resistance, is often non-effective (4,10).
Because CMV reactivation arises from impaired
CMV-speciﬁc T-cell immunity, various adoptive
transfer protocols have been developed to restore
cellular immunity against CMV (11e13).
The potential of adoptive transfer of CMV-
speciﬁc cytotoxic T lymphocyte (CTL) clones to
restore antiviral immunity after allogeneic stem cell
transplantation was ﬁrst shown by Ridell et al. (11).
This approach was based on selective propagation
of human CMV-speciﬁc CTL clones from bulk
donor lymphocytes in vitro, thus exploiting the ben-
eﬁts of donor lymphocyte infusion by transferring
CMV-speciﬁc T cells contained within the graft
while minimizing the risk of an acute graft-versus-
host disease (aGvHD). Although this approach is
effective, its application has several drawbacks. It is
very time-consuming and laborious to prepare suit-
able cell numbers necessary for an effective restora-
tion of CMV immunity. Patients with an acute CMV
infection need immediate medical treatment within
days, which does not comply with a protocol of in
vitro propagation of T-cell clones for several weeks.
Hence, such an in vitro approach is only effective
when performed pre-emptively.
Because only a minority of immunocompromised
patients have resistant CMV disease, and thus the
majority of cell products will never be used, such an
approach is by far too costly and labor-intensive to be
broadly introduced into the clinic. Moreover, the
potential risks for patients, including cross-contami-
nation or introduction of infectious agents into the
product during processing, must be considered, as
well as the manufacturing process that qualiﬁes the
cell product as an advanced therapy medicinal
product (ATMP) with all the regulatory complexities
associated with this product rating.
To overcome these difﬁculties regarding the
generation of antigen-speciﬁc T cells and its clinical
use, various approaches have been established aiming
for the direct ex vivo selection of virus-speciﬁc T cells
on the basis of magnetic-activated cell sorting
(MACS) technology.
The cytokine secretion assay (CSA) is based on
the capture—by means of bi-speciﬁc antibodies—of
cytokines, such as interferong, on the surface of the
memory/effector T cells that are induced to produce
and secrete cytokines on in vitro stimulation with therespective virus-peptides (14). Thus, after stimula-
tion (4e6 h), virus-reactive T cells can be labeled
selectively according to the bound cytokines and
subsequently enriched by MACS (15,16). With the
use of recombinant protein or peptide-pools con-
sisting of overlapping peptides spanning an entire
immunodominant protein, the CSA had already
been successfully used to simultaneously enrich
CMV-, Epstein-Barr virusespeciﬁc and adenovirus-
speciﬁc CD4þ T-helper cells and CD8þ CTLs
irrespective of human leukocyte antigen (HLA) re-
striction for therapeutic approaches. Yet, these
enrichment protocols were typically followed by
further in vitro culture (12,17e20).
The second approach for the enrichment of virus-
speciﬁc T cells uses the direct labeling of antigen-
speciﬁc T cells by means of multimeric peptide class
I major histocompatibility (MHC) complex staining
and subsequent sorting.
Tetrameric MHC class I peptide complexes are
soluble complexes of four synthetic biotinylated
b2-microglobulin/MHC monomers loaded with an
antigenic peptide and streptavidin. By use of multi-
merization, an exponential increase in avidity is
created to generate stable binding of MHC tetramer
MHC streptamer-selected CMV-speciﬁc T lymphocytes 1247complexes to its cognate T-cell receptors (TCRs).
Labeling of streptavidin, which functions as “back-
bone” for the tetramer complex with ﬂuorochromes
or magnetic microparticles, allows speciﬁc visualiza-
tion and prospective enrichment of antigen-speciﬁc
T cells in combination with ﬂuorescence-activated
cell sorting (FACS) or MACS.
Reversible MHC class I multimer staining is
performed with the use of the high afﬁnity of
d-biotin as a competitor for the binding sites of
Strept-Tactin, which can be applied as an analogue
of streptavidin and is therefore referred to as MHC
streptamer. Thus, multimeric peptide class I MHC
complexes, which use the binding of Strep-tag II to
Strept-Tactin to form complexes, can be easily
disassembled by the addition of d-biotin. Because of
their low afﬁnity, peptide MHC class I monomers
dissociate from their TCR spontaneously within
seconds (Figure 1) (21).
On account of this and in contrast to conven-
tional non-reversible MHC tetramer stainings,
reversible MHC streptamer staining does not
noticeably alter T-cell function or activate T cells
through cross-linking TCRs—which, in the absence
of co-stimulatory signals—can lead to induction of
apoptosis and in addition excludes possible toxic or
immunogenic side effects owing to conferred multi-
mer complexes on the cell surface (22).
However, both multimeric MHC class I pep-
tide staining techniques have been successfully
used for enrichment of CMV-speciﬁc CTLs for
clinical use (23,24).Figure 2. Gating strategy used for the determination of the frequency of v
were excluded from the analysis by gating out 7-AADepositive cells. T
(prior enrichment, negative fraction and the ﬁnal enriched product) areThis study aimed at transferring the laboratory-
scale MHC streptamer-based isolation of CMV-
speciﬁc donor CTLs into a clinical-scale, Good
Manufacturing Practice (GMP)-compliant process
in preparation of a phase I/II clinical trial in patients
with recurrent CMV viremia after stem cell
transplantation.Methods
Donor inclusion
Mononuclear cells (MNC) were collected by means
of apheresis from healthy donors who were tested for
the presence of CMV-speciﬁc CTLs (>0.02% CMV-
speciﬁc CTLs among CD3þ T cells). CMV-speciﬁc
CTLs were stained with the use of MHC streptamers
as described later, and the frequency of CMV-spe-
ciﬁc CTLs was determined according the gating
strategy shown in Figure 2.
The study protocol was approved by the local
ethics committee, and donors gave written informed
consent.Preparation of magnetic MHC streptamer beads
All manufacturing steps were performed under full
GMP conditions in the GMP facility of the
German Red Cross Blood Donor Service Baden-
Württemberg-Hessen, Frankfurt am Main, with a
manufacturing authorization from the municipal gov-
ernment within a federally approved Paul Ehrlichiable CMV-speciﬁc CD8þ CTLs among CD3þ T cells. Dead cells
he frequency (purity) of CMV-speciﬁc CTLs within each fraction
shown for 7-AADenegative CD3þ lymphocytes.
1248 M. Odendahl et al.Institute clinical trial or as part of a process validation
in the GMP facility of the Department of Medicine I,
University Hospital of Dresden.
All starting materials for the large-scale magnetic
enrichment of CMV-speciﬁc CTLs, including MHC
streptamers and magnetic beads, were manufactured
for the purpose of clinical application in GMP-like
manner. For release of the starting materials, the
batches were further analyzed for identity, sterility
and purity and formally released for clinical use by
the Department of Quality Management of the
German Red Cross Blood Donation Service Baden-
Württemberg-Hessen, Frankfurt am Main, or by the
Quality Management Department of Medicine I,
University Hospital of Dresden. For the magnetic
enrichment of CMV-speciﬁc CTLs from non-
mobilized MNC apheresis, 0.750 mg of magnetic
beads and 1 mg of MHC class I peptide (both Stage
Cell Therapeutics, Göttingen, Germany) were mixed
in a 500-mL transfer bag (Fresenius, Bad Homburg,
Germany). CliniMACS buffer (Miltenyi Biotec,
Bergisch Gladbach, Germany) was added to yield a
ﬁnal volume of 100 mL and incubated for at least 1 h
at 4C. To remove free unbound MHC class I pep-
tide monomers, the transfer bag was connected to a
CliniMACS Tubing Set TS (Miltenyi Biotec), and
enriched magnetic MHC streptamer beads were
collected with the use of Depletion Program 1.2.Isolation of CMV-speciﬁc CTLs
For each magnetic enrichment process, 1.04  1010
leukocytes (median, range; 7.0  108 to 2.6  1010)
from a non-mobilized MNC apheresis were trans-
ferred into transfer bags (Fresenius) and CliniMACS
buffer (Miltenyi Biotec) containing 20% human
serum albumin (HSA) (Baxter, Unterschleißheim,
Germany) was added to yield a ﬁnal volume of
approximately 500 mL. Cells were washed twice
(210g for 20 min without brake at 4C) to remove
platelets. After resuspension in CliniMACS buffer
yielding a cell concentration of 2  107 cells/mL,
cells were incubated with magnetic MHC streptamer
beads for 20 min at 4C under constant agitation.
Unbound magnetic beads were removed by washing
the cells twice with CliniMACS buffer/20% HSA
(centrifugation, 340g for 20 min with brake at 4C).
Cells were resuspended in 200 mL of CliniMACS
buffer, and magnetically labeled cells were isolated
with the use of the CliniMACS, CliniMACS Tubing
Set LS and CD34 selection II program (all Miltenyi
Biotec). CliniMACS buffer was added to the
enriched cell fraction to a ﬁnal volume of 100 mL.
To obtain untouched antigen-speciﬁc CTLs, the
MHC magnetic streptamers were released by incu-
bation of the isolated cells twice in d-biotin solution(Stage Cell Therapeutics) (ﬁnal concentration of
1 mmol/L) for 20 min at 4C under constant shaking.
Released MHC streptamers were removed by
washing the cells with CliniMACS buffer (340g for
20 min at 4C). The release of MHC streptamers by
addition of d-biotin was repeated, followed by
washing the enriched cells twice with 500 mL of
CliniMACS buffer (340g for 20 min at 4C). The
cells were resuspended in 5e10 mL of HSA. From
the positive fraction, 2 mL was taken to determine the
number of CMV-speciﬁc CTLs and of residual non-
CMV-speciﬁc, potentially allo-reactive T cells within
the sample as well as product sterility. The complete
enrichment process was performed under a laminar
ﬂow bench (class A) in a clean room (class B).Calculations and statistical analyses
To enumerate the cell number of white blood cells
(WBC), lymphocytes, monocytes, granulocytes and
platelets, a Sysmex XT-1800i (Sysmex, Norderstedt,
Germany) was used.
For the determination of the frequency of
CD3þ, CD4þ, CD8þ, CD14þ, CD19þ, CD45þ
and CD56þ cells by ﬂow cytometry, CD3/CD8/
CD45/CD4, CD14/CD45 BD Multitest kit, anti-
CD19 ﬂuorescein isothiocyanate (FITC) and CD56
antigen-presenting cells (APC), as well as Calibur
and Cellquest software or, as an alternative, a
FacsCanto II in combination with FacsCanto Soft-
ware (all reagents and software BD Biosciences,
Heidelberg, Germany), were used.
Purity of CMV-speciﬁc CTLs in the ﬁnal cell
product was deﬁned as the frequency of CMV-speciﬁc
CD8þ T cells among living CD3þ lymphocytes (see
gating strategy, Figure 1). Absolute cell number
of CMV-speciﬁc CTLs was calculated as follows:
number of WBC  frequency of CMV-speciﬁc CTLs
among CD3þ T cells  volume. Data are expressed
as mean, standard deviation, median and range. To
compare groups for statistically signiﬁcant differences,
the GraphPad prism program (GraphPad Software,
La Jolla, CA, USA) and a two-sided Student’s t-test
for unpaired data were used. A result was considered
signiﬁcant at the 5% level of signiﬁcance. Linear
regression analyses were used when mentioned.MHC streptamers
The following Strep-tagged MHC class I peptides
were used for the multimerization with either
phycoerythrin (PE)-conjugated or magnetic beade
conjugated Strep-Tactin complexes: MHC class I
HLA-A*0101 CMV pp50245e253 (VTEHDTLLY),
HLA-A*0201 CMV pp65495e503 (NLVPMVATV),
HLA-A*0201 CMV IE-1316e324 (VLEETSVML),
MHC streptamer-selected CMV-speciﬁc T lymphocytes 1249MHC class I HLA-B*0702 CMV pp65417e426
(TPRVTGGGAM) and HLA-A*2402 CMV
pp65341e349 (QYDPVAALF). All reagents were ob-
tained from IBA Stage Cell Therapeutics. MHC
streptamer-PE were multimerized within 2e4 h
before staining by incubation of Strep-Tactin PE and
MHC class I peptide (both IBA Stage) in cell wash
(BD Biosciences) for 1 h at 4C in the dark.Staining of CMV-speciﬁc CTLs by MHC streptamer PE
The purity of enriched CMV-speciﬁc CTLs was
calculated on the basis of MHC streptamer PE staining
and ﬂow cytometric analysis with the use of a FACS
Calibur and CellQuest Pro software or FacsCanto II
and FacsCanto software (all BD Biosciences).
In brief, approximately 0.2e1  106 peripheral
bloodmononuclear cells of each fraction were stained
with relevant MHC streptamer PE for 10 min at 4C,
followed by incubation with anti-CD3 FITC and
anti-CD8 APC (both BD Biosciences) for 20 min at
4C in the dark. Cells were washed2with pharmlyse
buffer and resuspended with cell wash buffer (both
BD Biosciences). To exclude dead cells from analysis
and determine the viability of cells, either 7-actino-
aminomycin D (7-AAD) (BD Biosciences) or propi-
dium iodide (PI) (Sigma Aldrich) was added before
FACS analysis to each sample. 7-AADepositive or
PI-positive events were regarded as dead cells.Testing of MHC streptamer release by Western blot
The presence of MHC class I peptides on cells of a
CMV HLA-A*0201-speciﬁc human T-cell line was
tested by means of Western blot analysis; 1  105
cells of a CMV HLA-A*0201-speciﬁc T-cell line
were lysed with a high salt buffer (200 mmol/L
NaCl) for 15 min on ice and used for Western blot
analysis under non-reducing conditions. Cell ly-
sates were run over a 10% polyacrylamide gel and
blotted in the cold room (4C). The membrane was
then blocked with blocking buffer (phosphate-
buffered saline, 5% Tween and 5% milk powder)
for 1 h at room temperature. The detection of
Strep-tag MHC class I peptides were carried out
with the use of Strep-Tactinehorseradish peroxi-
dase (1:4000) in blotting buffer followed by incu-
bation with Western lightning chemiluminescence
reagent plus (PerkinElmer Life Sciences, Rodgau-
Jügesheim, Germany) according to the manufac-
turer’s speciﬁcations.Cytotoxicity
Cytotoxic activity of the streptamer-isolated CTLs
was tested against unloaded or peptide-pulsedHLA-A*0201-positive T2 cells in a 4-h standard 51Cr-
release assay. Brieﬂy, T2 cells were loaded with the
HLA-A*0201-restricted CMVpp65 peptide at a con-
centration of 50 mg/mL for 3 h and labeled with 100
mCi51Cr (sodium chromate, Perkin-Elmer Life Sci-
ences) for 1 h at 37C in 1 mL of Roswell Park Me-
morial Institute 1640 medium. 51Cr-labeled target
cells were washed three times and plated in round-
bottomed 96-well plates. CTLs that were stored
approximately 16e18 h at 4C after MHC streptamer
isolation were added in triplicates to 5  103 CMV
peptide-pulsed, 51Cr-labeled T2 target cells in wells of
a 96-well plate at effector celletoetarget cell ratios of
10:1, 20:1 or 40:1. As negative control, isolated T cells
were added to unloaded andT2 target cells loadedwith
an irrelevant human immunodeﬁciency virus (HIV)
peptide incubated under identical conditions. After 4 h
of incubation, 100 mL of supernatant was collected
from each well, and the released 51Cr was determined
in a beta-counter (PerkinElmer Life Sciences).
Maximal and spontaneous release was measured by
treating labeled cells with 2% Triton X-100 (Ferak,
Berlin, Germany) or medium alone, respectively. The
depicted results represent the mean values of triplicate
determinations for three different T-cell enrichments
(Figure 5); bars indicate standard error of the mean.
The speciﬁc cytotoxicity was calculated accord-
ing to the formula:
Percent speciﬁc lysis ¼ 100  [(counts per min-
ute [cpm] experimental release minus cpm sponta-
neous release)/(cpm maximal release minus cpm
spontaneous release)].Sterility testing
Growth of aerobic and anaerobic bacteria was tested
by inoculating 0.5 mL of the ﬁnal cell product and
4.5 mL of supernatant from the last washing step
BacT/Alert ﬂasks (bioMerieux, Nürtingen, Ger-
many), respectively. The BacT/Alert ﬂasks were then
incubated for 7 days according to the manufacturer’s
instructions, and growth of bacteria was recorded
with the use of an automated microbial detection
system (bioMerieux). Positive readings were sent to
the Department of Microbiology of Goethe Univer-
sity Medical Centre, Frankfurt am Main, for conﬁr-
mation and bacteria identiﬁcation. Only conﬁrmed
positive samples were considered contaminated.Results
Magnetic enrichments with the use of ﬁve different MHC
streptamers
A total of 22 processes from 21 MNC aphereses were
performed with the use of ﬁve different MHC
1250 M. Odendahl et al.streptamers (MHC class I/HLA-A*0101 CMV pp50
[VTEHDTLLY], HLA-A*0201 CMV pp65 [NLV-
PMVATV], HLA-A*0201 CMV IE-1 [VLEETSV-
ML], HLA-B*0702 CMV pp65 [TPRVTGGGAM]
and HLA-A*2402 pp65 [QYDPVAALF]). The pu-
rity of CMV-speciﬁc T cells among CD3þ T cells in
each fraction of the enrichment process was calcu-
lated according to the MHC streptamer staining and
the gating strategy shown in Figure 2. The median
percentage of CMV-speciﬁc T cells within the
apheresis product was 0.41% among CD3þ T cells
(ranging from 0.03% to 14.8%). The isolation pro-
cess resulted in a median purity of 90.2% (range:
17.7e99.5%) among CD3þ T cells and a viability of
91.5% (range: 75.0e100.0%). Starting from 1.04 
1010 leukocytes (range: 0.07e2.59  1010) contained
in the MNC apheresis, the isolation process yielded a
total number of 7.77  106 (range: 0.11e31.00 
106) CMV-speciﬁc CTLs, representing an overall
median enrichment factor of 2541 (range:
105e27,440) for CMV-speciﬁc CTLs (Table I).
The composition of the ﬁnal cell product with
regard to different lymphocytes population varied
and is depicted in Table II (see also supplementary
Figure 1). Brieﬂy, the majority of lymphocytes
comprised CD3þ T cells (median: 66.0%, range:
23.0e95.0%), of which CD8þ T cells accounted
for 47.1% (range: 19.8e91.5%). CD19þ B cells
accounted for 9.95% (range: 0.2e77.5%) of total







WBCs [1  1010 cells] 1.10  0.48 1.04 (0.07e2.59)
CD3þ T cells
[1  109 cells]
5.42  3.49 5.64 (0.03e1.61)
CMV-speciﬁc T cells
[1  107 cells]
5.05  11.36 1.14 (0.16e53.28)
CMV-speciﬁc T cells [%] 1.21  3.11 0.41 (0.03e14.8)
After enrichment
WBCs [1  107 cells] 3.18  3.08 1.93 (0.11e13.1)
CD3þ T cells
[1  107 cells]
1.72  2.04 1.25 (0.04e9.03)
CMV-speciﬁc T cells
[1  106 cells]
12.59  18.01 7.77 (0.11e31.00)
CMV-speciﬁc T cells [%] 75.1  27.5 90.2 (17.7e99.5)
Viability [%] 92.0  8.11 91.5 (75.0e100.0)
Recovery [%] 100.2  153.7 67.2 (0.9e139.2)
Enrichment factor 4868  7168 2541 (105e27,440)
Details of leukapheresis material (before enrichment) and the ﬁnal
product are given for each enrichment process. Absolute cell count
for WBCs, CD3þ T cells and CMV-speciﬁc CTLs as well as
frequency of CMV-speciﬁc CTLs are given before and after
enrichment. Recovery of CMV-speciﬁc CTLs and enrichment
efﬁcacy are shown.exceeding CD4þ T cells (median: 7.7%, range:
1.3e41.0%) and CD56þ natural killer (NK) cells
(median: 1.6%, range: 0.0e20.4%), respectively.
Among leukocytes (WBC), the median frequency
of lymphocytes within the ﬁnal cell product was
74.9% (range: 23.3e96.9%). The median frequency
of monocytes and granulocytes accounted for 12.0%
(range: 1.0e64.7%) and 6.7% (range: 0.2e57.7%)
of leukocytes, respectively.
No correlation was found between the frequency
of CMV-speciﬁc CTLs within the MNC apheresis
and in the ﬁnal cell product (P ¼ 0.214) or between
the purity of CMV-speciﬁc CTLs and other cell
populations within the ﬁnal cell product (B cells, NK
cells, monocytes, granulocytes or platelets; data not
shown), which implies that the presence of these cell
populations in general does not predict or impair the
efﬁciency of the enrichment process itself. Most
importantly, the usage of the two most frequently
used MHC streptamers (n > 5) showed no signiﬁ-
cant differences with regard to the purity of CMV-
speciﬁc CTLs within the ﬁnal cell product
(Table III). The obtained median purity of 95.4%
of CMV-speciﬁc CTLs in the ﬁnal cell product with
the use of HLA-B*0702 CMV pp65 streptamers
(range: 82.6e98.6%) was not signiﬁcantly higher
(P ¼ 0.08) compared with the median purity of
90.1% when HLA-A*0201 CMV pp65 streptamers
(range: 17.7e99.5%) were used. Also, no signiﬁcant
difference was detected between the purity of
enriched CMV-speciﬁc CTLs with the use of HLA-
A*2401 CMV pp65 (median purity: 30.7%, range:
29.9e88.7%) and HLA-A*0201 CMV pp65
(P ¼ 0.16). Signiﬁcant differences were observedTable II. Cell composition of ﬁnal cell product.
Mean  standard
deviation Median (range)
Lymphocytes/WBCs [%] 72.1  20.2 74.9 (23.3e96.9)
Monocytes/WBCs [%] 14.8  16.0 12.0 (1.0e64.7)
Granulocytes/WBCs [%] 12.2  14.5 6.7 (0.2e57.7)
Platelets [1  107/mL] 6.8  8.4 4.9 (0.7e32.7)
CD3þ T cells/
lymphocytes [%]
66.4  25.1 66.0 (23.0e95.0)
CD4þ T cells/
lymphocytes [%]
10.8  10.2 7.7 (1.3e41.0)
CD8þ T cells/
lymphocytes [%]
53.8  21.9 47.1 (19.8e91.5)
CD19þ B cells/
lymphocytes [%]
28.6  27.1 9.95 (0.2e77.5)
CD56þ NK cells/
lymphocytes [%]
3.4  4.8 1.6 (0.0e20.4)
The frequency and absolute cell count of leukocytes subpopulation
and platelets within the ﬁnal product were determined by Sysmex
1800i. The frequency of CD3þ, CD4þ and CD8þ T cell sub-
populations, CD19þ B cells and CD56þNK cells was determined
by FACS and is given as frequency among living lymphocytes.
Table III. Purity of CMV-speciﬁc CTLs within the ﬁnal cell







HLA-A*0101 CMV pp50 1 36.7
HLA-A*0201 CMV pp65 11 73.4  27.9 90.10 (17.7e99.5)
HLA-A*0201 CMV IE-1 1 97.8
HLA-B*0702 CMV pp65 6 93.4  6.0 95.4 (82.6e98.6)
HLA-A*2402 CMV pp65 3 49.8  33.7 30.7 (29.9e88.7)
Total 22 75.1  27.8 90.2 (17.7e99.5)
MHC streptamer-selected CMV-speciﬁc T lymphocytes 1251when comparing the yielded purity with the use of
HLA-B*0702 CMV pp65 streptamers and HLA-
A*2401 CMV pp65 (P ¼ 0.048). The purities after
the enrichment with the use of HLA-A*0101 CMV
pp50 (36.7%) and HLA-A*0201 CMV IE-1 (97.8%)
streptamers were not considered for statistical anal-
ysis because of their infrequent usage (Table III).
However, most importantly, highly signiﬁcant
differences (P ¼ 0.003) with regard to the obtained
purities of the MHC streptamer-enriched CMV-
speciﬁc CTLs in the ﬁnal cell product could be
observed when comparing MHC streptamer enrich-
ments before 2010 and thereafter (Figure 3). The
median purity of CMV-speciﬁc CTLs from 14 MHC
streptamer selection processes before the year 2010
was 70.7% (ranging from 17.7% to 97.8%). In
contrast, median purity of eight MHC streptamer
selections thereafter was 95.2% (ranging from 90.3%
to 99.5%; Table IV), which clearly indicates an
improvement with regard to process efﬁciency and
reproducibility over time.Figure 3. Purity of CMV-speciﬁc CTLs within the ﬁnal cell
products. Purity of CMV-speciﬁc CTLs within the ﬁnal cell
products from enrichment processes before 2010 and 2010 and
later is given as median frequency with range. Statistically signiﬁ-
cant differences between groups are depicted as P values.Dissociation of MHC streptamers from T cells
To obtain fully functional antigen-speciﬁc T cells for
therapeutic use, MHC streptamers were designed to
dissociate from their cognitive TCRs after the addi-
tion of d-biotin (22). The dissociation of MHC
streptamers was demonstrated by means of staining a
human CMV pp65-speciﬁc CTL line generated from
an MHC class I/HLA-A*0201/CMV pp65-positive
donor with MHC streptamer PE (Figure 4A,B). After
addition of d-biotin, the staining intensity was
reduced to the level of unstained cells (Figure 4A),
which demonstrates loss of Strep-Tactin PE bound to
the CTLs. The presence of MHC monomers after
dissociation was further analyzed by Western blotting.
MHC streptamers were detected within the cell lysate
of 1  105 cells stained with MHC streptamer PE.
After dissociation with d-biotin, MHC streptamers
could not be detected within a cell lysate of stained
cells, which demonstrates dissociation of MHC
monomers from the TCRs caused by the low afﬁnity
when not complexed as multimers (Figure 4B).Cytotoxic potential of MHC streptamer-enriched
CMV-speciﬁc CTLs
The potency displayed by the antigen-speciﬁc cyto-
toxicity is the most crucial functional parameter for
the success of this cell therapy. To conﬁrm the
cytotoxic potential of MHC, streptamer-enriched
CMV pp65-speciﬁc CTLs isolated from three
healthy donors were tested against unloaded or
peptide-pulsed HLA-A*0201 T2 cells in a 4-h stan-
dard 51Cr-release assay (25) at various effector
celletoetarget cell ratios. CMV pp65-speciﬁc CTLs
efﬁciently lysed T2 cells (mean: 77.5%  15.5%)
loaded with the CMV pp65 peptide at an effector
celletoetarget cell ratio of 40:1. In contrast, unloa-
ded T2 cells and T2 cells loaded with an irrelevant
HLA-A*0201-restricted HIV peptide (pol) were only
lysed to a marginal extent (mean: 8.6%  3.6% or
9.1%  0.5%, respectively) (Figure 5).Viability of MHC streptamer-enriched T cells after
magnetic enrichment
To test viability of T cells contained within the ﬁnal
cell product, PI incorporation into the DNA of cellsTable IV. Purity of CMV-speciﬁc CTLs among CD3þ T cells in






Before 2010 14 63.5  29.1 70.7 (17.7e97.8)
After 2010 and later 8 90.3  3.2 95.2 (90.3e99.5)
Figure 4. Release of MHC streptamers from CMV-speciﬁc CTLs. (A) Flow cytometric detection of CMV pp65-MHC class I streptamer PE
on a CMV pp65-speciﬁc CTL line. A human T-cell line speciﬁc for CMV pp65495e503 was stained with MHC streptamer-PE and disso-
ciated with d-biotin as described in the Methods section. (B) CMV-speciﬁc CTL line (1  105) stained as shown in A were lysed and used
for Western blot analysis. The presence of MHC streptamers was detected by an enzymatic reaction of Strep-Tactinehorseradish peroxidase
with its substrate.
1252 M. Odendahl et al.with compromised plasma membrane integrity was
determined by means of ﬂow cytometry as described.
T cells enriched by means of MHC streptamer
technology and CliniMACS were stored for up to 72
h at 4C, and the cell viability was determined
immediately after enrichment as well as after 24 h, 48
h and 72 h of storage at 4C. Immediately after
enrichment, viability of T cells exceeded 95%. After
24 h, the cell viability still amounted to 90.0% and




CMV reactivation is a signiﬁcant clinical problem
after allogeneic HSCT; in particular, patients with
CMV infections refractory to antiviral drugs have a
high mortality rate. Antiviral drugs are also associ-
ated with substantial toxicity (responsible for severe
neutropenia) and the development of late-onset
CMV disease. CMV disease is strongly correlated
with the impairment of CMV-speciﬁc T cellFigure 5. Cyotoxic potential of MHC streptamer isolated CMV-
speciﬁc CTLs within the ﬁnal cell product. HLA-A*0201 CMV
pp65 streptamer-isolated CTLs cells from three magnetic enrich-
ment processes were added to 5  103 CMV peptide (pp65) or
HIV (pol)-pulsed, 51Cr-labeled T2 target cells per well at effector
celletoetarget cell ratios of 10:1, 20:1 or 40:1. Results represent
the mean values of triplicate determinations of these three
enrichment processes; bars indicate standard error of the mean.immunity after the conditioning treatment. Thus, the
reconstitution of CMV-speciﬁc T cell immunity by
adoptive T cell transfer has been proposed for the
treatment of chemotherapy-refractory CMV disease
(11), and several clinical studies have shown its
efﬁcacy in patients requiring minimal or no immu-
nosuppression (11,23,24). Adoptive transfer of
non-manipulated donor lymphocytes also proved
beneﬁcial for the management of CMV and Epstein-
Barr virus infections yet is often associated with an
aGvHD caused by the presence of excessive doses of
alloreactive T cells (26,27). Minimizing the risk of an
aGvHD achieved by the generation of CMV-speciﬁc
T cell clones by repeated stimulation of donor lym-
phocytes with the respective antigen showed the full
potential of adoptive transfer of CMV-speciﬁc T cells

































Figure 6. Viability and shelf life of MHC streptamer-selected
CTLs within the ﬁnal cell product. HLA-A*0201 CMV pp65-
specifc CTLs enriched by MHC streptamer technology and
CliniMACS from three healthy donors were stored for up to 72 h
at 4C, and the cell viability was determined immediately after
enrichment (0 h), 24 h, 48 h and 72 h storage at 4C by ﬂow
cytometric detection of 7-AAD incorporation into the DNA of
dead cells. Means and standard deviations are given.
MHC streptamer-selected CMV-speciﬁc T lymphocytes 1253MHC streptamers are based on multimer tech-
nology and allow fast isolation of fully functional
antigen-speciﬁc T cells but, in contrast to MHC
tetramers, can be easily detached from T cells by
addition of d-biotin (22). The complete release of the
MHC streptamers from the T cell surface is a crucial
requirement for the isolation of “minimally manip-
ulated” and functionally unaltered T cells for clinical
use. MHC streptamer-isolated T cells do not enter
apoptosis or tolerance as reported for the conven-
tional MHC class I tetramers through their remain-
ing stimulus via their TCRs in the absence of
co-stimulatory factors presented by professional
APC (29e32). Additionally, the risk of possible toxic
or immunogenic side effects owing to conferred
multimer complexes on the cell surface is minimized.
The Paul Ehrlich Institute and the European Medi-
cines Agency have therefore conﬁrmed these advan-
tages and granted HLA class I streptamer-puriﬁed T
cells the status of “minimally manipulated” cell
products, which are not classiﬁed as ATMPs. This
classiﬁcation substantially facilitates the broader
application of MHC streptamer-puriﬁed T cells for
clinical use.
However, the use of MHC streptamer technology
requires the knowledge of immunodominant epi-
topes of the antigen of interest and the availability of
the respective MHC class I molecule used for the
production of MHC streptamers. Because both
knowledge and availability have considerably
increased within the last decade, the number of
various MHC streptamers that can be used for the
isolation of CTLs with various antigen speciﬁcities
has also continuously grown and with that, the
number of eligible patients.
It remains worth mentioning that concerns about
the efﬁcacy of the adoptive transfer of CMV-speciﬁc
CTLs alone, without the co-transfer of CD4þ T-
helper cells, have repeatedly been refuted by
demonstration that adoptively transferred CMV-
speciﬁc CTLs are able to mediate sustained protec-
tive immunity to CMV (23,24). Whether or not the
survival and functionality of the adoptively trans-
ferred antigen-speciﬁc CTLs depend on the presence
of T-helper cells remains to be determined.Results on enrichment efﬁcacy
In the present study, we demonstrated the successful
transfer of the laboratory-scale MHC streptamer
isolation of CMV-speciﬁc donor CTLs into a clin-
ical-scale GMP-compliant process for a phase I/II
clinical trial in patients with recurrent CMV viremia
after HSCT. In total, we performed 22 MHC
streptamer-based magnetic enrichments.The purity, recovery and number of CMV-
speciﬁc cytotoxic T cells within the ﬁnal product are
essential because these parameters deﬁne the dose of
transferable, presumably non-alloreactive T cells
with known speciﬁcity and therefore the potential
beneﬁt and risk for the patient. The yielded purity,
recovery and viability of CMV-speciﬁc T cells are
comparable to studies in which MHC class I
tetramer technology for the isolation of CMV-spe-
ciﬁc CTLs was used (23,33). The purity exceeded
the yielded purities of CMV-speciﬁc T cells through
the use of the CSA technology (17,18). Overall, the
achieved purity in this work allows the safe admin-
istration of a substantial number of CMV-speciﬁc
CTLs while at the same time minimizing the risk of
co-transferring signiﬁcant numbers of potentially
alloreactive T cells. However, a number of MHC
streptamer selections resulted in poor purity
(frequency <50%). Similar purities of CMV-speciﬁc
CTLs yielded from magnetic selection had been re-
ported from other authors who used conventional
non-reversible MHC class I tetramer staining
methods followed by enrichment with the use of anti-
PE microbeads. Keenan et al. (33) report purities of
91% of enriched HLA-A*0201 CMV pp65-speciﬁc
T cells among CD8þ T cells after two subsequent
magnetic enrichment processes (range:13.0e99.8%)
(33). Slightly higher purities were reported by Cob-
bold et al. (23) (median: 98.8%; range: 10e99.5%).
Both authors also report on individual selections with
poor purities of CMV-speciﬁc T cells within the ﬁnal
cell product.
To improve the quality of the enrichment pro-
cess, we sought to identify the pivotal elements that
are likely to have an impact on purity.
First, we searched for the seemingly most obvious
reason for an effective enrichment process, that is,
the frequency of CMV-speciﬁc CTLs within the
apheresis product.
We were not able to ﬁnd a clear correlation of
signiﬁcance between the frequency of CMV-speciﬁc
CTL prior enrichment (contained within the apher-
esis product) and within the ﬁnal cell product (r2 ¼
0.06). Yet, considering the variation regarding the
detected initial frequency of HLA-A*0201 CMV
pp65, HLA-B*0702 and HLA-A*2401 CMV pp65-
speciﬁc CTLs, the initial frequency of CMV-speciﬁc
T cells within MNCs of the apheresis product is
likely to have contributed to the relative poor purity
observed in individual cases.
In comparing the yielded purities with regard to
the MHC streptamer usage, we observed enrich-
ments through the use of HLA-B*0702CMV pp65
exceeding the performance of the remaining MHC
streptamers. Whereas the performance of HLA-
A*2402 CMV pp65 was signiﬁcantly reduced
1254 M. Odendahl et al.compared with HLA-B*0702 CMV pp65 (P ¼
0.048), no signiﬁcant differences were observed be-
tween HLA-B*0702 CMV pp65 and HLA-A*0201
CMV pp65 (P ¼ 0.079).
The purity after the enrichment with the use of
HLA-A*0101 CMV pp50 and HLA-A*0201 CMV
IE-1 streptamers was not considered for statistical
analysis because of their rare/infrequent usage
(Table III). Furthermore, the impact of the presence
of CD19þ B cells, CD56þ NK cells, monocytes,
granulocytes or platelets with regard to the purity of
CMV-speciﬁc T cells within the ﬁnal product was
investigated. Their presence showed no correlation
with the purity of CMV-speciﬁc CTLs, which in-
dicates that the efﬁciency of the enrichment process
is not affected by their presence.
The most striking signiﬁcant difference with re-
gard to the purities of CMV-speciﬁc CTLs within the
ﬁnal cell product was observed when comparing the
efﬁciency of MHC streptamer selection processes
before 2010 and thereafter. Taking into account that
there were no changes with regard to the MHC
streptamer selection process itself, it must be
assumed that stability and shelf life of MHC strep-
tamers have had a direct impact on the efﬁciency of
the enrichment processes. From 2010 on, no peptide
MHC class I monomers that had been stored more
than 3 months at 80C after shipment were used
for multimerization.
Therefore, although the stability and shelf life
of various MHC streptamers used for the enrichment
of CMV-speciﬁc CTLs has not been analyzed in detail,
we assume that the stability and shelf life of peptide
MHC class I monomers contributed signiﬁcantly to the
efﬁciency of the MHC streptamer selection processes.
However, in the present report, we discuss com-
plex enrichment processes performed over a period of
more than 7 years. Therefore, many factors, such as
gaining experience with the enrichment process, the
development and improvements of standardized
operation procedures required for the production and
quality control and eventually the stability of MHC
streptamers, must be considered when establishing an
efﬁcient enrichment process of antigen-speciﬁc CTLs.Potency and viability of the enriched CMV-speciﬁc CTLs
within the ﬁnal cell product
The cytotoxic potential of the CMV-speciﬁc CTLs for
up to 24 h after enrichment was conﬁrmed by the
speciﬁc lysis of CMV peptide-loaded T2 cells after 4-h
co-incubation with CMV pp65-speciﬁc CTLs from
three different enrichment processes used for vali-
dating the process. MHC streptamer-isolated CTLs
contained within the tested ﬁnal cell products showed
superior functional properties with regard to speciﬁckilling of CMV pp65-loaded target cells, showing the
potency of the CMV-speciﬁc CTLs within the ﬁnal
cell product for therapeutic approaches. To test sta-
bility during storage, cell viability of the ﬁnal cell
product was tested up to 72 h after enrichment or 96 h
after MNC collection, respectively. After 24-h storage
at 2e6C after enrichment, cell viability within all
tested ﬁnal products exceeded 90%, meeting the pre-
deﬁned minimal speciﬁcation requirements of 80%.
The observed mean viability of 81.6% after 48-h
storage also fulﬁlled these minimal requirements,
although viability of individual cell products might
slightly vary, resulting in slightly poorer cell viability
and thus failing the minimal speciﬁcation require-
ment. In conclusion, the cell stability appeared to be
given for at least up to 48 h, which will provide
enough time to ship the ﬁnal cell product to any
transplant center. However, this would require the
validation of the potency, which was in our case only
validated for a storage time of 24 h.Safety
The sterility of the ﬁnal products was tested after the
selection process. No growth of aerobic or anaerobic
bacteria with the use of an automated microbial
detection system testing was reported.Conclusions
The MHC streptamer technologyebased approach
to isolate CMV-speciﬁc CTLs results, owing to the
reversibility of MHC streptamer binding in “mini-
mally manipulated,” functional T cells, are—
according to the verdict of the Committee for
Advanced Therapies at the European Medicines
Agency—not considered as an ATMP. The major
advantage of the MHC streptamer technology is its
full GMP compliance. The T cells are stable for up
to 48 h after puriﬁcation (72 h after MNC collec-
tion), thus allowing enough time to transfer cells to
the respective transplant center.Acknowledgments
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